ESMO 2020 – Congress digest on Lung Cancer – virtual
Preface – ESMO 2020
Preface - ESMO 2020 Byoung Chul Cho, MD, PhD - Division of Medical Oncology, Yonsei Cancer Center - Yonsei University College of Medicine - Seoul, South Korea Dear Colleagues, The ESMO Virtual Congress 2020 has attracted more than 30,000 registrants from over 150 countries to whom content presented at more than 70 sessions has been made available. The 2,137 abstracts reported at the conference included 87 late breaking abstracts. Sessions were provided for 135 proffered papers, 195 mini ora
Immune checkpoint inhibition: chemotherapy-free regimens & new PD-1 inhibitors on the horizon
Immune checkpoint inhibition: chemotherapy-free regimens & new PD-1 inhibitors on the horizon Monotherapy versus chemotherapy Five-year update of KEYNOTE-024 Pembrolizumab as single agent for up to 35 cycles has been shown to be superior to 4 to 6 cycles of platinum-doublet chemotherapy in patients with metastatic non–small-cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS) ≥ 50 % in the KEYNOTE-024 trial.
Early-stage lung cancer: noteworthy findings for different types of therapy
Early-stage lung cancer: noteworthy findings for different types of therapy Phase III data regarding postoperative radiation Postoperative radiotherapy (PORT) in patients with completely resected NSCLC has been a subject of debate for years.
Determinants of treatment success in small-cell lung cancer
Determinants of treatment success in small-cell lung cancer Predictive characteristics in CASPIAN … The randomized, controlled, open-label, phase III CASPIAN trial has assessed first-line treatment with durvalumab ± tremelimumab plus platinum/etoposide (EP) compared to EP alone in patients with extensive-stage small-cell lung cancer (ES-SCLC).
Innovative and established approaches for patients with uncommon mutations
Innovative and established approaches for patients with uncommon mutations CROWN: first-line use of ALK inhibitor lorlatinib The highly potent, brain-penetrant, third-generation ALK tyrosine kinase inhibitor lorlatinib has been widely approved for the treatment of patients with ALK-positive advanced NSCLC who have previously received ALK TKIs.
EGFR-targeted options in a changing treatment landscape
EGFR-targeted options in a changing treatment landscape Amivantamab plus lazertinib The combination of amivantamab, a bispecific antibody that targets both EGFR and MET, and the potent third-generation EGFR TKI lazertinib is being explored in patients with advanced NSCLC.
Interview – Malignant mesothelioma: implementation of immunotherapy-based standards
Interview – Malignant mesothelioma: implementation of immunotherapy-based standards Paul Baas, MD, PhD, Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands Which outcomes can be expected in European patients with malignant mesothelioma who receive the current standard treatment? After 4 to 6 courses of standard chemotherapy with platinum and pemetrexed, we can expect a median overall survival of around 15 or 16 months.
Interview – Exploring interactions between radiotherapy and the immune system
Interview – Exploring interactions between radiotherapy and the immune system Maarten Lambrecht, MD, PhD, Department of Oncology, KU Leuven – University of Leuven, Belgium The modulation of molecular pathways that determine the patient response to radiotherapy might contribute to improving patient outcomes. What insights have been gained to date in this field of research that may be relevant in the years to come? There is indeed a growing interest in the field of radiobiology a
DOWNLOADS
All downloads from ESMO 2020 Lung Cancer – virtual
Full report (english)
Full report (mandarin)
The ESMO Virtual Congress 2020 has attracted more than 30,000 registrants from over 150 countries to whom content presented at more than 70 sessions has been made available.
ESMO 2020 – Congress digest advanced Solid Tumours – virtual
Milestones of PD-1 inhibition in gastric and esophageal cancer
Milestones of PD-1 inhibition in gastric and esophageal cancer Gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, and esophageal adenocarcinoma are substantial causes of cancer-related mortality worldwide and have poor 5-year overall survival (OS) when diagnosed at an advanced stage [1, 2].
Getting innovation from the laboratories into clinical practice
Getting innovation from the laboratories into clinical practice Andrés Cervantes, MD, PhD, Department of Medical Oncology, Hospital Clinic Universitario, Biomedical Research institute INCLIVA, University of Valencia, Spain Which data presented at ESMO 2020 in the field of gastric cancer, gastroesophageal junction adenocarcinoma and esophageal cancer do you deem practice-changing? The ESMO congress has provided amazing new data on gastroesophageal cancer, and great contributions by
Ovarian cancer: taking PARP inhibition one step further
Ovarian cancer: taking PARP inhibition one step further Individualized dosing of niraparib Niraparib has been approved as maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer (OC) based on the results of the NOVA trial [1]. The starting dose used in NOVA was 300 mg orally daily.
Novel combination approaches in various solid tumors
Novel combination approaches in various solid tumors Lenvatinib plus pembrolizumab The anti-angiogenic multikinase inhibitor lenvatinib has been shown to exert immunomodulatory effects that enhance the anti-tumor activity of anti-PD-1 antibodies [1]. In the early-phase setting, lenvatinib plus pembrolizumab induced partial responses in patients with different tumor types [2].
DOWNLOADS
All downloads from ESMO 2020 Solid Tumours – virtual
Full report (english)
Full report (mandarin)
The ESMO congress has provided amazing new data on gastroesophageal cancer, and great contributions by different authors all over the world have been presented. Patients with advanced gastric cancer used to have a median overall survival of less than 1 year when treated with conventional chemotherapy. For the first time, this was prolonged to more than 1 year due to the addition of checkpoint inhibition.
